XBiotech Statistics
Total Valuation
XBiotech has a market cap or net worth of $74.09 million. The enterprise value is -$41.37 million.
Important Dates
The last earnings date was Thursday, May 14, 2026.
| Earnings Date | May 14, 2026 |
| Ex-Dividend Date | n/a |
Share Statistics
XBiotech has 30.49 million shares outstanding. The number of shares has increased by 0.05% in one year.
| Current Share Class | 30.49M |
| Shares Outstanding | 30.49M |
| Shares Change (YoY) | +0.05% |
| Shares Change (QoQ) | n/a |
| Owned by Insiders (%) | 25.09% |
| Owned by Institutions (%) | 6.79% |
| Float | 22.84M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | n/a |
| Forward PS | n/a |
| PB Ratio | 0.55 |
| P/TBV Ratio | 0.55 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Financial Ratio HistoryEnterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 39.03
| Current Ratio | 39.03 |
| Quick Ratio | 38.60 |
| Debt / Equity | n/a |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | n/a |
Financial Efficiency
Return on equity (ROE) is -25.93% and return on invested capital (ROIC) is -281.80%.
| Return on Equity (ROE) | -25.93% |
| Return on Assets (ROA) | -18.81% |
| Return on Invested Capital (ROIC) | -281.80% |
| Return on Capital Employed (ROCE) | -35.38% |
| Weighted Average Cost of Capital (WACC) | 9.00% |
| Revenue Per Employee | n/a |
| Profits Per Employee | -$461,621 |
| Employee Count | 87 |
| Asset Turnover | n/a |
| Inventory Turnover | n/a |
Taxes
In the past 12 months, XBiotech has paid $255,000 in taxes.
| Income Tax | 255,000 |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -16.84% in the last 52 weeks. The beta is 0.86, so XBiotech's price volatility has been lower than the market average.
| Beta (5Y) | 0.86 |
| 52-Week Price Change | -16.84% |
| 50-Day Moving Average | 2.43 |
| 200-Day Moving Average | 2.53 |
| Relative Strength Index (RSI) | 47.11 |
| Average Volume (20 Days) | 24,177 |
Short Selling Information
The latest short interest is 184,007, so 0.60% of the outstanding shares have been sold short.
| Short Interest | 184,007 |
| Short Previous Month | 174,079 |
| Short % of Shares Out | 0.60% |
| Short % of Float | 0.81% |
| Short Ratio (days to cover) | 6.75 |
Income Statement
| Revenue | n/a |
| Gross Profit | n/a |
| Operating Income | -48.41M |
| Pretax Income | -39.91M |
| Net Income | -40.16M |
| EBITDA | -46.83M |
| EBIT | -48.41M |
| Earnings Per Share (EPS) | -$1.32 |
Full Income StatementBalance Sheet
The company has $115.46 million in cash and n/a in debt, with a net cash position of $115.46 million or $3.79 per share.
| Cash & Cash Equivalents | 115.46M |
| Total Debt | n/a |
| Net Cash | 115.46M |
| Net Cash Per Share | $3.79 |
| Equity (Book Value) | 135.02M |
| Book Value Per Share | 4.43 |
| Working Capital | 114.05M |
Full Balance SheetCash Flow
In the last 12 months, operating cash flow was -$42.17 million and capital expenditures -$195,000, giving a free cash flow of -$42.36 million.
| Operating Cash Flow | -42.17M |
| Capital Expenditures | -195,000 |
| Depreciation & Amortization | 1.58M |
| Net Borrowing | n/a |
| Free Cash Flow | -42.36M |
| FCF Per Share | -$1.39 |
Full Cash Flow StatementMargins
| Gross Margin | n/a |
| Operating Margin | n/a |
| Pretax Margin | n/a |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
